Perioperative Analgesic Efficiency of Quadratus Lumborum Block vs Epidural in Radical Cystectomy

September 24, 2020 updated by: National Cancer Institute, Egypt

Perioperative Analgesic Efficiency of Ultrasound Guided Quadratus Lumborum Block Versus Epidural Analgesia in Bladder Cancer Patients Undergoing Radical Cystectomy

This study is performed to measure the perioperative analgesic efficiency of bilateral quadratus lumborum block versus epidural analgesia in bladder cancer patients undergoing radical cystectomy

Study Overview

Detailed Description

  1. Background and rationale:

    Bladder cancer is the ninth most common cancer in the world while being considerably common in both developed and developing countries. Bladder cancer is the most common malignancy among Egyptian males and it had been previously attributed to Schistosoma infection, a major risk factor for squamous cell carcinoma (SCC). Recently, transitional cell carcinoma (TCC) incidence has been increasing while SCC has declined. Exposures to tobacco smoke, occupational toxins, and environmental sources of heavy metals such as arsenic are the major reported risk factors for TCC .

    Acute perioperative pain management has been a matter of attention especially in major abdominal surgeries like radical cystectomy. Poor perioperative pain management especially with major abdominal surgeries can lead to deterioration of both physiological and psychological status of the patient leading to anxiety, stress, and patient's dissatisfaction while also leading to severe abdominal pain and diminished respiratory functions due to impaired function of accessory respiratory muscles which may precipitate shallow breathing, atelectasis, retained secretions, and also lack of patient's cooperation.

    Adequate multimodal perioperative pain management improves patient's recovery and survival on a general prospective due to decreased surgical stress response leading to better immunological functions and coagulation profile, and hence improving the outcome of the surgery.

    Perioperative epidural analgesia has been associated with improved overall survival but not reduced cancer recurrence. However, patients receiving epidural analgesia with or without general anesthesia have shown longer survival over 5 years period postoperatively than those receiving general anesthesia alone which can be related to better immunological profile and decreased stress response in regional anesthesia group of patients.

    Epidural analgesia for perioperative pain management has proven earlier recovery in post anesthesia care unit (PACU) with better pain and respiratory tolerance and decreased need for intravenous opioid administration. Perioperative continuous epidural analgesia was found to reduce hospital stay for patients undergoing major abdominal surgeries.

    Quadratus lumborum (QL) block was first described by Blanco and was previously called (the posterior approach of TAP block). Volunteers for QL spread of local anesthetic have shown a good spread of local anesthetics from T4 to L1 proving adequacy of QL block for analgesia over both posterior and anterior abdominal region surgeries. Further studies are being made to assess the adequacy of QL block as an analgesic technique for major abdominal surgeries.

    Perioperative analgesia using QL block with the ipsilateral technique following minor abdominal surgeries has shown decreased need for intravenous administration of opioids and has also shown promising results for adequate perioperative analgesia after major abdominal surgeries.

    Many reports have suggested that QL block can provide adequate analgesia not only for abdominal wall somatic pain but for severe visceral pain as well. The mechanism for visceral pain analgesia is not fully understood but it is suggested to be due to paravertebral spread of the injected local anesthetic.

    Early post-operative ambulation of bladder cancer patients undergoing radical cystectomy can be achieved using QL block which have a positive impact on both surgical outcome and patient survival. Radical cystectomy patients receiving QL block have shown decreased hospital stay with earlier discharge due to adequate long lasting analgesia and early ambulation.

  2. Objectives:

    Primary Outcome:

    To test feasibility, efficiency, and safety of continuous perioperative QL block for perioperative pain management in bladder cancer patients undergoing radical cystectomy in comparison to continuous perioperative epidural analgesia for the same surgical procedure.

  3. Study Design:

    • This study will be Prospective Randomized Controlled Study.
    • The study will be submitted to the Institutional Review Board (IRB) for review.
  4. List of Correlative Studies:

    • Blanco R, Ansari T, Girgis E (2015): Quadratus lumborum block for postoperative pain after caesarean section: a randomised controlled trial. European Journal of Anaesthesiology (EJA). 32(11):812-8.
    • Blanco R, Ansari T, Riad W, & Shetty N (2016). Quadratus lumborum block versus transversus abdominis plane block for postoperative pain after cesarean delivery: a randomized controlled trial. Regional anesthesia and pain medicine, 41(6), 757-762.
  5. Study Methods:

    • Interventions:

    Pre-interventional preparation:

    • Sedation for all patients prior to analgesic procedure at preoperative preparatory room using midazolam (0.02 mg/kg) intravenously.
    • Patients will be re-instructed about our anesthetic procedure steps according to each group.
    • Standard ASA monitoring for all patients before and during the anesthetic procedure.
    • Anesthetic procedure will start at the preoperative preparatory room in the form of regional block according to each of the study groups with catheter insertion and assessment of procedure success as discussed later.
    • Patients will be subjected to either quadratus lumborum block or epidural catheter insertion and analgesia as described later on.
    • Success of catheter insertion will be evaluated using 5ml of lidocaine 5% per catheter injection before proceeding with regular anesthetic doses. Analgesia level of T4 will be satisfactory for permitting transfer of patients to OR to proceed with general anesthesia and surgical procedure.
    • Routine assessment of all patients including assessment of patient's medical history, clinical examination, laboratory investigations (kidney and liver functions, CBC, and coagulation profile), ECG will be conducted on all patients above 40 years old and echocardiography for patients with suspected cardiomyopathies by medical history or preoperative examination. Chest X-ray for all patients suspected for respiratory diseases.
    • Patients will be subjected to continuous monitoring during surgery for any further complications related to anesthetic techniques and to surgery itself.
    • Patients will be monitored at PACU post-operatively to ensure hemodynamic stability, adequate analgesia, and attention for any possible complications that may occur due to anesthetic or surgical techniques used.
    • Patients will be discharged using the modified Aldrete's scoring system, a score of 9 or more will be sufficient for safe discharge of the patient to ward for further monitoring, continuation of analgesic techniques, and assessment of adequacy of analgesia post-operatively.
    • Patients' discharge time till reaching sufficient Aldrete's score for each study group will be calculated and included in the study parameters for further assessment of safety and efficiency of analgesic techniques used.

      • Possible risks:

    • Orthostatic hypotension.
    • Hemodynamic instability (e.g. bradycardia, ECG changes, tachycardia).
    • Local anesthetic toxicity.

      • Source of Funding:

    No source of funding.

    • Time plan:

      • The study is to be started in 2018 and is expected to be finished in 2020.
      • The expected publishing date is 2020.
    • Benefits from the study:

    To test feasibility, efficiency, and safety of continuous perioperative QL block for perioperative pain management in bladder cancer patients undergoing radical cystectomy in comparison to continuous perioperative epidural analgesia for the same surgical procedure.

    • Possible Risk:

    • Orthostatic hypotension.
    • Hemodynamic instability (e.g. bradycardia, ECG changes, tachycardia).
    • Local anesthetic toxicity.
  6. Protection of privacy and confidentiality of patients' information:

    Data collection and presentation will be anonymous and both privacy and confidentiality will be protected to the maximal possible standards.

  7. Publication policy:

Any article arising from this work will carry the names of all participants with the name orders according to the degree of contribution to data interpretation and manuscript writing. Additional external authors may be added if they add to the content and qualify for authorship by the international standards.

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt, 11796
        • National Cancer Institute - Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • ASA II-III
  • Adult patients (>18 years old)
  • Both sexes
  • Scheduled for radical cystectomy at NCI, CU

Exclusion Criteria:

  • Patient's refusal of the study procedures
  • Allergy to drugs used in the study
  • Patients with chronic pain
  • Patients with coagulopathies (INR > 1.6 or platelets count < 50,000 cc3)
  • Hemodynamically unstable patients (e.g. BP < 90/60)
  • Patients with local or intra-abdominal infections concerning intervention sites and septic patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Quadratus Lumborum Block
17 cases will be subjected to bilateral Ultrasound-guided Quadratus lumborum block through bilateral catheter insertion for perioperative analgesia.

Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.

This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block

Other Names:
  • Transmuscular QL
ACTIVE_COMPARATOR: Epidural Analgesia
17 cases will be subjected to epidural catheter insertion for perioperative analgesia (as a control group).

With Patients placed in sitting position, puncture site will be identified at (T8-9, T9-10, or T10-11) intervertebral spaces. Using aseptic conditions, an 18G Tuohy epidural needle will be used to insert epidural catheter as appropriate.

Induction of epidural analgesia with 10-15 ml bupivacaine 0.25% preoperatively with top up doses of 5-7 ml bupivacaine 0.25% or equivalent administered judiciously till we achieve analgesic level of T4 to L1. The calculated top up doses will be administered each hour using bupivacaine 0.25% or by using a continuous infusion syringe pump for equivalent doses

Other Names:
  • Thoracic Epidural

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual analogue pain (VAS) score measurement postoperatively
Time Frame: 0 Hours Postoperatively
The primary outcome measures visual analogue pain scores in the two groups at the end of surgery
0 Hours Postoperatively
Visual analogue pain (VAS) score measurement 6 hours postoperatively
Time Frame: 6 Hours Postoperatively
The primary outcome measures visual analogue pain scores in the two groups 6 hours postoperatively
6 Hours Postoperatively
Visual analogue pain (VAS) score measurement 24 hours postoperatively
Time Frame: 24 Hours Postoperatively
The primary outcome measures visual analogue pain scores in the two groups 24 hours postoperatively
24 Hours Postoperatively
Visual analogue pain (VAS) score measurement 48 hours postoperatively
Time Frame: 48 Hours Postoperatively
The primary outcome measures visual analogue pain scores in the two groups 48 hours postoperatively
48 Hours Postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative Nausea and Vomiting
Time Frame: 48 Hours Postoperatively
Postoperative Nausea and Vomiting using nausea score (0 for none, 1 for mild to moderate nausea, 2 for moderate nausea, 3 for severe nausea accompanied by vomiting) When patient's nausea score reaches ≥ 2; intravenous anti-emetics in the form of Ondasetron 8mg and will be administered and recorded in all groups
48 Hours Postoperatively

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Morphine Usage
Time Frame: 48 Hours Postoperatively
During pain assessment using visual analogue score, if VAS score is ≥ 4, intravenous morphine 3mg will be administered 18. The mean first time for morphine requirement will be recorded in all groups (mean+- SD). Total 48 h morphine consumption will be recorded in all groups
48 Hours Postoperatively
Patient's satisfaction
Time Frame: 48 Hours Postoperatively
Patient satisfaction with the technique and analgesia to be assessed at the end of study (at 48 hours period) and will be put on a scale from 1 to 4 (poor = 1, fair = 2, good = 3, excellent = 4)
48 Hours Postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Ahmed H. Bakeer, M.D., National Cancer Institute, Cairo University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

November 15, 2018

Primary Completion (ACTUAL)

September 15, 2020

Study Completion (ACTUAL)

September 15, 2020

Study Registration Dates

First Submitted

August 12, 2019

First Submitted That Met QC Criteria

October 18, 2019

First Posted (ACTUAL)

October 21, 2019

Study Record Updates

Last Update Posted (ACTUAL)

September 25, 2020

Last Update Submitted That Met QC Criteria

September 24, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain, Postoperative

Clinical Trials on Quadratus Lumborum Block Using Bupivacaine 0.2%

3
Subscribe